SLG
MDGL icon

Stanley-Laman Group’s Madrigal Pharmaceuticals MDGL Stock Holding History

Stanley-Laman Group’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-2,447
Closed -$211K – 284
2019
Q3 		$211K Hold
2,447
– – 0.05% 256
2019
Q2 		$256K Buy
+2,447
New +$262K 0.06% 246

Other funds holding MDGL

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Stanley-Laman Group's MDGL Position: Q4 2019 in Review

Stanley-Laman Group sold out of Madrigal Pharmaceuticals (MDGL) in Q4 2019, closing a stake of 2,447 shares — an estimated $211K sold.

Stanley-Laman Group first reported a position in MDGL in Q2 2019 and held it in 2 quarters. The position peaked at $256K in Q2 2019. 120 funds tracked by Wall St. Rank hold MDGL as of Q4 2019.

  • Stanley-Laman Group reported no remaining Madrigal Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Stanley-Laman Group sold 2,447 Madrigal Pharmaceuticals shares in Q4 2019, an estimated $211K.
  • Stanley-Laman Group first reported a position in Madrigal Pharmaceuticals in Q2 2019 and held it in 2 quarters.
  • Stanley-Laman Group's Madrigal Pharmaceuticals position peaked at $256K in Q2 2019.
  • 120 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q4 2019.

Based on Stanley-Laman Group's 13F filing for Q4 2019, filed 4 Feb 2020.